LY686017 + paroxetine + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Social Phobia
Conditions
Social Phobia
Trial Timeline
Dec 1, 2004 → Jan 1, 2007
NCT ID
NCT00191022About LY686017 + paroxetine + placebo
LY686017 + paroxetine + placebo is a phase 2 stage product being developed by Eli Lilly for Social Phobia. The current trial status is completed. This product is registered under clinical trial identifier NCT00191022. Target conditions include Social Phobia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191022 | Phase 2 | Completed |
Competing Products
20 competing products in Social Phobia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Cariprazine + Placebo | AbbVie | Approved | 85 |
| Quetiapine | AstraZeneca | Approved | 85 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Phase 2/3 | 65 |
| Seroquel + Sugar Pill | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Approved | 85 |
| Pristiq + Placebo | Pfizer | Approved | 84 |
| Venlafaxine ER | Pfizer | Phase 3 | 76 |
| Ziprasidone + Sertraline | Pfizer | Phase 2 | 51 |
| Sertraline + Placebo | Pfizer | Approved | 84 |
| Nefazodone | Bristol Myers Squibb | Approved | 84 |
| Escitalopram | Lundbeck | Approved | 82 |
| Cipralex + Placebo | Lundbeck | Phase 2 | 49 |
| BHV-0223 + Placebo | Biohaven | Phase 2/3 | 60 |
| VQW-765 + Placebo | Vanda Pharmaceuticals | Phase 3 | 69 |
| PH94B | Vistagen Therapeutics | Phase 3 | 69 |
| Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray | Vistagen Therapeutics | Phase 2 | 44 |
| PH94B Nasal Spray + Placebo Nasal Spray | Vistagen Therapeutics | Phase 3 | 69 |